Feb 25, 2022 2:00am EST Immunocore receives positive CHMP opinion for KIMMTRAK® (tebentafusp) for the treatment of unresectable or metastatic uveal melanoma
Jan 26, 2022 7:00am EST Immunocore announces FDA approval of KIMMTRAK® (tebentafusp-tebn) for the treatment of unresectable or metastatic uveal melanoma
Dec 06, 2021 7:00am EST Immunocore announces initial Phase 1 data of ImmTAC® candidate IMC-C103C targeting MAGE-A4
Nov 10, 2021 7:00am EST Immunocore Reports Third Quarter 2021 Financial Results and Provides Business Update
Nov 09, 2021 8:01am EST Immunocore presents new data on tebentafusp in metastatic cutaneous melanoma (mCM) and uveal melanoma (mUM) at the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting
Oct 18, 2021 7:30am EDT Immunocore and Medison Pharma Partner for Future Commercialization of Tebentafusp in Canada, Central Eastern Europe, and Israel
Sep 22, 2021 6:00pm EDT Immunocore announces publication of phase 3 data comparing tebentafusp with investigator’s choice in The New England Journal of Medicine